2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2910

Work Productivity in Systemic Sclerosis and Association with Health Related Quality of Life
Abstract Number: 2911

A Comparison of Gastrointestinal Disease Severity in African American and Caucasian Scleroderma Patients
Abstract Number: 2912

Performance of the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Systemic Sclerosis -Associated Interstitial Lung Disease (SSc-ILD)
Abstract Number: 2913

Four Year Effects of Combined Bosentan and Iloprost Treatment on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion and Clinical Status, in Systemic Sclerosis Patients
Abstract Number: 2914

Association of Radiographic Findings in Hand X-Ray with Autoantibodies in Patients with Systemic Sclerosis
Abstract Number: 2915

An Increased Circulating Level of Periostin in Patients with Systemic Sclerosis: Associations with Functional Impairment in Various Affected Organs
Abstract Number: 2916

The Number of Micro-Haemorrhages and Micro-Thrombosis Detected By Nailfold Videocapillaroscopy Is a Good Predictor of Disease Activity in Systemic Sclerosis: The Validation Study of NEMO Score
Abstract Number: 2917

Nailfold Capillaroscopy and Mortality in Systemic Sclerosis
Abstract Number: 2918

The Clinical Relevance of Common ANA Patterns in Systemic Sclerosis
Abstract Number: 2919

Prevalence of Antiphospholipid Antibodies and Their Clinical Associations in Systemic Sclerosis: Data from a French Cohort
Abstract Number: 2920

The Effect of Rituximab on B Cells in Skin and Peripheral Blood in Systemic Sclerosis
Abstract Number: 2921

Patient Participation in Patient Reported Outcome Instrument Development in Systemic Sclerosis
Abstract Number: 2922

Disability, Fatigue, and Their Associates in Early Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 2923

T-Cell Receptor Signaling Inhibition By CC-90005, a Selective Protein Kinase C Theta Antagonist, Reduces Antigen Mediated T-Cell Activation and Arthritis Pathology in the Mouse CIA Model
Abstract Number: 2924

Terminally Differentiated CD8 T Cell Subset Has Distinct Signiture in RA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].